- Home
- ASO vs NAMS Comparison
ASO vs NAMS Comparison
Compare ASO & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASO | NAMS |
|---|---|---|
| Founded | 1938 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.5B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ASO | NAMS |
|---|---|---|
| Price | $57.89 | $32.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $58.08 | $46.75 |
| AVG Volume (30 Days) | ★ 1.3M | 761.2K |
| Earning Date | 06-09-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.54 | N/A |
| Revenue | ★ $6,053,414,000.00 | N/A |
| Revenue This Year | $5.13 | $17.96 |
| Revenue Next Year | $5.36 | $540.65 |
| P/E Ratio | $10.46 | ★ N/A |
| Revenue Growth | ★ 2.02 | N/A |
| 52 Week Low | $35.95 | $16.79 |
| 52 Week High | $62.45 | $42.00 |
Technical Indicators
Market Signals| Indicator | ASO | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 53.86 | 47.71 |
| Support Level | $57.09 | $29.73 |
| Resistance Level | $60.55 | $37.25 |
| Average True Range (ATR) | 2.47 | 1.68 |
| MACD | 0.26 | -0.04 |
| Stochastic Oscillator | 57.66 | 17.31 |
Price Performance
Historical ComparisonAbout ASO Academy Sports and Outdoors Inc.
Academy Sports and Outdoors Inc is engaged in the full-line sporting goods and outdoor recreation retailer in the United States. The company's product categories are outdoors, apparel, sports & recreation, and footwear.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.